Clinical Trials & Regulatory
-
Extensive PK studies and clinical trials have been completed by prior sponsor, NASA, in collaboration with Nastech and the US Navy. A New Drug Application (NDA) on a 505(b)2 pathway is being developed for submission to the FDA.
INSCOP
-
Two well-controlled parallel, double-blind phase III trials completed showing efficacy and safety
-
Over 1,000 patients have been dosed, with virtually no SAEs
-
Fast Track designation has been granted by the FDA
-
Work remains on CMC (i.g., stability batches)

Summary of Intranasal Scopolamine Hydrobromide Gel Studies
